10-Q: AbCellera Advances Two Therapies to Phase 1 Trials

AbCellera Biologics reports reduced operating losses and significant clinical pipeline advancements, initiating Phase 1 trials for two antibody therapies while maintaining a strong liquidity position.

Summary

• AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines.
• The company reported a net loss of $34.7 million for the three months ended June 30, 2025, an improvement from a $36.9 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $80.3 million, compared to $77.5 million for the same period in 2024.
• Total revenue significantly increased by 133% to $17.1 million for the three months ended June 30, 2025, primarily driven by a substantial rise in licensing revenue to $10.4 million from $0.4 million in the prior year.
• Total revenue for the six months ended June 30, 2025, increased by 23% to $21.3 million, with licensing revenue growing to $10.6 million from $0.6 million.
• Operating expenses decreased by 34% to $66.7 million for the three months ended June 30, 2025, largely due to a non-recurring impairment charge in the prior year's depreciation, amortization, and impairment expenses.
• Cash, cash equivalents, and marketable securities totaled $553.1 million as of June 30, 2025, a decrease of $72.5 million since December 31, 2024.
• Cash used in operating activities decreased to $44.0 million for the six months ended June 30, 2025, from $71.7 million in the prior year period.
• The company submitted Clinical Trial Applications (CTAs) to Health Canada for two internal therapies, ABCL635 (vasomotor symptoms) and ABCL575 (atopic dermatitis), and received No Objection Letters in May 2025.
• Phase 1 clinical trials for both ABCL635 and ABCL575 have been initiated in Canada during the second half of 2025.
• A third program, ABCL688 (autoimmunity), advanced into IND/CTA-enabling studies in Q2 2025, with an anticipated IND/CTA submission in 2026.
• Cumulative partner-initiated program starts with downstream participation reached 102, and 18 molecules have advanced into the clinic (up from 14).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company continues to incur net losses and its cash position has decreased, the significant improvement in operating loss, substantial increase in licensing revenue, and critical advancements of multiple internal programs into clinical trials are strong positive indicators for a biotechnology company. The stated 36-month liquidity runway also provides a degree of financial stability.

Positives

• Operating loss significantly improved for both the three-month ($49.6 million vs. $93.5 million) and six-month ($112.2 million vs. $148.3 million) periods ended June 30, 2025, compared to 2024.
• Total revenue increased substantially, driven by a significant rise in licensing revenue, indicating growing value from partnerships.
• Cash used in operating activities decreased by $27.7 million for the six months ended June 30, 2025, reflecting improved operational efficiency.
• Two internal antibody therapies, ABCL635 and ABCL575, successfully received Health Canada authorization and initiated Phase 1 clinical trials, marking critical advancements in the company's pipeline.
• A third internal program, ABCL688, advanced into IND/CTA-enabling studies, demonstrating continued pipeline progression.
• The company has a stated liquidity runway of at least 36 months from existing cash, cash equivalents, marketable securities, loan receivables, and government contributions, reducing immediate funding concerns.
• Completion of final large platform investments in the clinical manufacturing facility and corporate headquarters in 2025 is expected to significantly reduce future investing cash flows.

Negatives

• Net loss for the six months ended June 30, 2025, increased to $80.3 million from $77.5 million in the prior year, primarily due to lower 'other income' (which included a large non-cash fair value gain in 2024).
• Total cash, cash equivalents, and marketable securities decreased by $72.5 million since December 31, 2024.
• Milestone payments were $0 for both the three and six months ended June 30, 2025, down from $1.5 million in the prior year periods.
• Research fees decreased for the six-month period ended June 30, 2025, indicating a shift in partner activity or internal prioritization.
• Cash flow from investing activities shifted from a positive $82.0 million in 2024 to a negative $23.9 million in 2025, reflecting increased investments and reduced grant funding receipts.

Risks

• Incurred losses in certain years, including 2025, and may not be able to generate sufficient revenue to achieve profitability.
• Quarterly and annual operating results have fluctuated significantly in the past and may fluctuate in the future, making prediction difficult.
• Commercial success depends on the quality of antibody discovery and development capabilities, technological capabilities, advancement of internal programs, and their acceptance by partners.
• Failure to execute business strategy could adversely impact growth and profitability.
• Development of a biological molecule is inherently uncertain; no guarantee of marketing approval or commercial viability for antibody drug candidates.
• Partners have significant discretion in determining when and whether to make announcements about partnerships, which could affect share price.
• May not be able to file applications or amendments to commence additional clinical trials on expected timelines, or regulatory bodies may not permit progression.
• No marketed proprietary products and no independent clinical development experience, making assessment of future product candidate development difficult.
• Limited number of product candidates; significant delays or failure to obtain regulatory approval would materially adversely affect the business.
• Long-term prospects depend on discovering, developing, and commercializing additional product candidates, which may fail or suffer delays.
• Faces significant competition from more effective, safer, or less expensive products.
• Upgrading and integrating business systems (e.g., ERP) could result in implementation issues and business disruptions.
• Inability to obtain and maintain sufficient intellectual property protection or if scope is not broad enough, competitors could develop similar technologies.
• May become involved in lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Failure to maintain proper and effective internal control over financial reporting could harm operating results and business operations.
• Sales of a substantial number of common shares in the public market could cause share price to fall significantly.
• Impairment charges pertaining to goodwill, identifiable intangible assets, or other long-lived assets from mergers and acquisitions could have an adverse non-cash accounting impact.
• Market price of common shares may be volatile, leading to potential loss of investment.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and share price.
• Resource allocation to specific development candidates may forgo more profitable opportunities.
• Reliance on partners for downstream economic value means future success is dependent on their development and commercialization efforts, over which the company has no control.
• Investments in research and development efforts to enhance technology are risky and may not yield expected returns.
• Inability to enroll patients in clinical trials would prevent timely completion.
• Clinical trial design or execution may not support regulatory approval.
• Interim, preliminary, or top-line data from clinical trials may change as more data becomes available.
• Disruptions at health authorities and other government agencies could hinder timely development or approval.
• Successful development of current and future product candidates is uncertain, and development may be discontinued or reprioritized at discretion.
• Product candidates may have undesirable side effects that delay or prevent marketing approval or limit sales.
• Approved products may not achieve broad market acceptance among physicians, patients, and third-party payors.
• Failure to obtain approval or commercialize products outside the United States would limit full market potential.
• Manufacturing difficulties by the company or third-party manufacturers could delay or prevent supply.
• Material modifications in manufacturing methods or price controls imposed by governments may adversely affect future profitability.
• Current and future legislation may increase difficulty and cost to commercialize products and affect prices.
• Public health outbreaks and pandemics could adversely affect business operations and clinical trials.
• Business and relationships are subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy, and security laws.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Reliance on a limited number of suppliers for laboratory equipment and materials makes the company vulnerable to shortages and price fluctuations.
• Operating facilities becoming damaged or inoperable could jeopardize research and development efforts.
• Insurance policies may not cover all risks or be sufficient.
• Security breaches, loss of data, and other disruptions could compromise sensitive information.
• Loss of any member of senior management or inability to attract/retain talent could adversely affect business.
• Restructuring and reorganization activities may be disruptive or ineffective.
• Technology acquisitions and investments in other companies or technologies could negatively affect operating results, dilute ownership, or increase debt.
• Billing and collections processing activities are time-consuming, and delays could adversely affect revenue.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• Inability to protect confidentiality of information and trade secrets could harm business.
• May be subject to claims that employees, consultants, or contractors wrongfully used or disclosed confidential information of third parties.
• Inability to protect and enforce trademarks and trade names could harm competitive position.
• May be subject to claims challenging the inventorship of patents and other intellectual property.
• Litigation related to intellectual property could be time-intensive and costly.
• Obtaining and maintaining patent protection depends on compliance with various required procedures, and non-compliance could reduce or eliminate protection.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Use of open source software could compromise ability to offer data packages and lead to litigation.
• In-licensed intellectual property from government-funded programs may be subject to federal regulations like march-in rights.
• If the company or its non-U.S. subsidiary is a Controlled Foreign Corporation (CFC), there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders.
• U.S. shareholders may suffer adverse tax consequences if the company is characterized as a Passive Foreign Investment Company (PFIC).
• Tax authorities may disagree with tax positions and conclusions, resulting in unanticipated costs or non-realization of expected benefits.
• Changes in tax law could adversely affect business and financial condition.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Adverse developments affecting the financial services industry could adversely affect business operations and financial condition.

Future Outlook

The company anticipates initiating Phase 1 clinical trials for ABCL635 and ABCL575 in Canada during the second half of 2025, with ABCL635 Phase 1 data expected in mid-2026. An IND/CTA submission for ABCL688 is anticipated in 2026. Management believes existing liquidity will be sufficient to meet working capital and capital expenditure needs for at least the next 36 months, expecting a significant reduction in investing cash flows after completing final large platform investments in 2025.

Management Comments

• "We are a team of scientists, engineers, and business professionals focused on discovering and developing first-in-class and best-in-class antibody-based medicines for indications with high unmet medical need."
• "We think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development."
• "Our deals with partners emphasize participation in the success and upside of future antibody therapeutic candidates. We structure our agreements in a way that is designed to align our partners economic interests with our own."
• "During the second quarter of 2025, we achieved a critical regulatory milestone with the submission of Clinical Trial Applications (CTAs) to Health Canada for two of our therapies: ABCL635 and ABCL575."
• "The programs align with the Company's strategy of building value, both through strategic partnerships, and through internal discovery and development of potential first-in-class and best-in-class antibody therapies."
• "Based on our current business plan, we believe that our available liquidity from existing cash, cash equivalents, marketable securities, loan receivables, and government contributions, will be sufficient to meet our working capital and capital expenditure needs and do not anticipate the need of additional external funding over at least the next 36 months following the date of this report."
• "In 2025, we are on track to complete our final large platform investments in our clinical manufacturing facility and our corporate headquarters. With the completion of these large platform investments, we expect a significant reduction in investing cash flows, shifting our capital allocation from building capabilities to using them as we execute our strategy of building on our pipeline of first-in-class and best-in-class medicines."
• "The Company maintains its belief in the merits of its case and will continue to enforce its intellectual property portfolio worldwide." (regarding Bruker litigation)
• "The Company believes that Plaintiffs claim is meritless and frivolous in all respects and intends to defend itself appropriately." (regarding Schrader litigation)

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology industry, specializing in antibody discovery and development. Its strategy of advancing both internal programs and strategic partnerships aligns with industry trends seeking to accelerate drug development and diversify revenue streams through milestone payments and royalties. The focus on 'first-in-class and best-in-class' antibody therapies positions it within the high-value segment of the biopharmaceutical market. The company acknowledges the impact of healthcare reform measures, including the Inflation Reduction Act, and the ongoing threat of biosimilar competition, which are significant factors across the pharmaceutical landscape.

Comparison to Industry Standards

• The company's business model, emphasizing downstream milestone and royalty payments from partnerships, is a common approach in the early-stage biotechnology sector, aligning its economic interests with partners' commercial success.
• Advancing two internal programs (ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis) into Phase 1 clinical trials is a significant de-risking step for a clinical-stage biotech, as many early-stage companies struggle to move candidates beyond preclinical stages. For example, industry-wide success rates from Phase 1 to approval are typically low (around 10-15%), but initiating these trials is a crucial milestone.
• The development of ABCL575 as an OX40-ligand-targeting antibody engineered for once every 6 months dosing aims for a differentiated profile, potentially offering a competitive advantage in the inflammatory and autoimmune space compared to existing therapies requiring more frequent administration.
• The cumulative 18 molecules in the clinic, including partner-led programs like those with Eli Lilly (Bamlanivimab, Bebtelovimab) and Denali Therapeutics (TAK-920/DNL919), demonstrates a robust pipeline progression rate compared to many smaller biotechs, although several NBL programs are paused.
• The investment in and completion of a clinical manufacturing facility is a strategic move towards vertical integration, similar to larger biopharmaceutical companies, aiming to reduce reliance on third-party contract manufacturing organizations (CMOs) and potentially accelerate timelines, though it requires significant capital outlay and operational expertise.

Corporate Governance

Legal Proceedings

• Ongoing patent infringement litigation against Bruker Cellular Analysis (formerly Berkeley Lights, Inc.) in the United States District Court for the District of Delaware. An eight-day jury trial is scheduled for January 2026.
• The United States Court of Appeals for the Federal Circuit (CAFC) confirmed the validity of AbCellera's 408 Patent in May 2025, rejecting Bruker's appeal regarding IPR2021-1249.
• Civil lawsuit filed by Sabariah Schrader, Executrix of the Estate of John William Schrader et al. against the company and its CEO in the Supreme Court of British Columbia, alleging breach of implied partnership/joint venture and patent infringement of Canadian patent No. 2,655,511. The company is seeking dismissal of certain affiliates for lack of jurisdiction, believing the claim is meritless.

Related Party Transactions

• The company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, for the construction of future office and laboratory headquarters.
• As of June 30, 2025, the equity investment balance in Dayhu JV was $41.7 million, and the company had a loan receivable balance of $33.8 million directly with Dayhu.
• As of June 30, 2025, the equity investment balance in Beedie JV was $48.7 million, and the company had a loan receivable balance of $36.2 million directly with Beedie.
• The company recorded a right-of-use asset of $47.2 million and an operating lease liability of $48.1 million associated with an office lease with the Dayhu JV.
• In May 2025, the company commenced a 20-year lease for office and laboratory space with the Beedie JV, recognizing a lease liability of $66.4 million and a corresponding right-of-use asset.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancements and strategic partnerships, but also exposure to continued losses, cash burn, and stock price volatility. Dilution risk from future equity issuances is noted.
• Employees: Restructuring activities in November 2023 (10% headcount reduction) may impact morale and retention, but continued investment in R&D and internal pipeline suggests ongoing opportunities.
• Customers/Partners: Continued focus on strengthening discovery and development capabilities aims to deliver more promising molecules and accelerate drug discovery, benefiting existing and new strategic partners.
• Creditors: The company's strong liquidity position (36-month runway) and government contributions provide confidence in its ability to meet financial obligations.
• Regulatory Authorities: Ongoing compliance with SEC reporting, healthcare laws, and intellectual property regulations is critical for continued operations and market access.

Next Steps

• Initiate Phase 1 clinical trials for ABCL635 and ABCL575 in Canada during the second half of 2025.
• Present data from the ABCL635 Phase 1 study in mid-2026.
• Anticipate submission of an IND/CTA for ABCL688 in 2026.
• Complete final large platform investments in the clinical manufacturing facility and corporate headquarters in 2025.
• Continue to enforce intellectual property portfolio worldwide, including the jury trial against Bruker scheduled for January 2026.
• Seek dismissal of certain company affiliates from the Sabariah Schrader et al. v. Carl Lars Genghis Hansen, et al. lawsuit for lack of jurisdiction.

Key Dates

Recommendation

The company is making significant strides in advancing its internal pipeline into clinical trials, a crucial de-risking event for a biotechnology firm. The improved operating loss and reduced cash burn from operations, coupled with increased licensing revenue, suggest a more efficient business model. The stated 36-month liquidity runway provides a solid financial foundation for continued development. However, the company remains unprofitable, and the overall net loss increased for the six-month period due to non-operating factors. The ongoing IP litigation also presents a notable risk. For a seasoned investor, the clinical progress is a strong positive, but the financial challenges warrant a 'hold' position, awaiting further clinical data and sustained improvements in profitability.

Keywords

Biotechnology, Antibody Discovery, Drug Development, Clinical Trials, Biologics, Pharmaceutical, Immunology, Oncology, Endocrinology, Women's Health, SEC Filing, 10-Q, ABCL, Therapeutics, R&D, Intellectual Property, Licensing Revenue